knowledge -WSS

knowledge

author：explore 2025-09-27 19:50:02 - browse：668

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： DeSantis talks Trump, trans issues and 'what wokeness is'

WSS

Driven by the pandemic, applicants flood public health schools

Ending racial health disparities hinges on penalties, political will

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Excited delirium, Elijah McClain, and emergency physicians

UCSF medical school apologizes for unethical prisoner experiments

Just how powerful is the placebo effect?

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Hollywood unions extend contract negotiations for actors

The Sacklers, horror, and ‘The Fall of the House of Usher’

Medical records are filled with copy

Biotech incubator Curie.Bio graduates its first startup

Cancer drug shortages should be causing more outrage

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

What does generative AI mean for health care? We asked experts

Just how powerful is the placebo effect?

focus

The Sacklers, horror, and ‘The Fall of the House of Usher’

FDA approves Recor Medical high blood pressure device

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Medicare will require more price transparency from hospitals

Judge rejects Trump's request to move Stormy Daniels hush

knowledge

knowledge

hotspot

hotspot